Literature DB >> 7913580

Mutational analysis of patients with neurofibromatosis 2.

M MacCollin1, V Ramesh, L B Jacoby, D N Louis, M P Rubio, K Pulaski, J A Trofatter, M P Short, C Bove, R Eldridge.   

Abstract

Neurofibromatosis 2 (NF2) is a genetic disorder characterized by the development of multiple nervous-system tumors in young adulthood. The NF2 gene has recently been isolated and found to encode a new member of the protein 4.1 family of cytoskeletal associated proteins, which we have named merlin. To define the molecular basis of NF2 in affected individuals, we have used SSCP analysis to scan the exons of the NF2 gene from 33 unrelated patients with NF2. Twenty unique SSCP variants were seen in 21 patients; 10 of these individuals were known to be the only affected person in their kindred, while 7 had at least one other known affected relative. In all cases in which family members were available, the SSCP variant segregated with the disease; comparison of sporadic cases with their parents confirmed the de novo variants. DNA sequence analysis revealed that 19 of the 20 variants observed are predicted to lead to a truncated protein due to frameshift, creation of a stop codon, or interference with normal RNA splicing. A single patient carried a 3-bp deletion removing a phenylalanine residue. We conclude that the majority of NF2 patients carry an inactivating mutation of the NF2 gene and that neutral polymorphism in the gene is rare.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913580      PMCID: PMC1918355     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  17 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

Review 2.  NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update.

Authors:  J J Mulvihill; D M Parry; J L Sherman; A Pikus; M I Kaiser-Kupfer; R Eldridge
Journal:  Ann Intern Med       Date:  1990-07-01       Impact factor: 25.391

3.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

Authors:  J A Trofatter; M M MacCollin; J L Rutter; J R Murrell; M P Duyao; D M Parry; R Eldridge; N Kley; A G Menon; K Pulaski
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

4.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.

Authors:  M H Ruttledge; J Sarrazin; S Rangaratnam; C M Phelan; E Twist; P Merel; O Delattre; G Thomas; M Nordenskjöld; V P Collins
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

5.  The neurofibromatosis type 2 gene is inactivated in schwannomas.

Authors:  E C Twist; M H Ruttledge; M Rousseau; M Sanson; L Papi; P Merel; O Delattre; G Thomas; G A Rouleau
Journal:  Hum Mol Genet       Date:  1994-01       Impact factor: 6.150

6.  DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree.

Authors:  M MacCollin; T Mohney; J Trofatter; W Wertelecki; V Ramesh; J Gusella
Journal:  JAMA       Date:  1993-11-17       Impact factor: 56.272

7.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

Authors:  J A Trofatter; M M MacCollin; J L Rutter; J R Murrell; M P Duyao; D M Parry; R Eldridge; N Kley; A G Menon; K Pulaski
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

8.  Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas.

Authors:  M P Rubio; K M Correa; V Ramesh; M M MacCollin; L B Jacoby; A von Deimling; J F Gusella; D N Louis
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

9.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

10.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.

Authors:  G A Rouleau; P Merel; M Lutchman; M Sanson; J Zucman; C Marineau; K Hoang-Xuan; S Demczuk; C Desmaze; B Plougastel
Journal:  Nature       Date:  1993-06-10       Impact factor: 49.962

View more
  23 in total

1.  Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas.

Authors:  L R De Vitis; A Tedde; F Vitelli; F Ammannati; P Mennonna; U Bigozzi; E Montali; L Papi
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

2.  Glioblastoma multiforme presenting as bilateral internal auditory canal tumors.

Authors:  J W Lee; M Houtchens; F Hochberg; B Price; Lev M; M Cunnane; R Pfannl; M MacCollin
Journal:  J Neurol       Date:  2006-03-20       Impact factor: 4.849

3.  Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.

Authors:  C L Wu; N Thakker; W Neary; G Black; R Lye; R T Ramsden; A P Read; D G Evans
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

4.  Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2.

Authors:  S M Messerli; Y Tang; M Giovannini; R Bronson; R Weissleder; X O Breakefield
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

Review 5.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

6.  Eleven novel mutations in the NF2 tumour suppressor gene.

Authors:  D Bourn; G Evans; S Mason; S Tekes; L Trueman; T Strachan
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

Review 7.  Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction.

Authors:  J A Girault; G Labesse; J P Mornon; I Callebaut
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

8.  Development of NF2 gene specific, strictly sequence defined diagnostic microarray for deletion detection.

Authors:  Kiran K Mantripragada; Patrick G Buckley; Caroline Jarbo; Uwe Menzel; Jan P Dumanski
Journal:  J Mol Med (Berl)       Date:  2003-06-27       Impact factor: 4.599

9.  Scanning the first part of the neurofibromatosis type 1 gene by RNA-SSCP: identification of three novel mutations and of two new polymorphisms.

Authors:  P Gasparini; L D'Agruma; G Pio de Cillis; P Balestrazzi; R Mingarelli; L Zelante
Journal:  Hum Genet       Date:  1996-04       Impact factor: 4.132

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.